PetVivo Holdings, Inc. (NASDAQ:PETV - Get Free Report) CEO John Lai purchased 150,000 shares of the business's stock in a transaction on Monday, April 15th. The shares were bought at an average cost of $0.60 per share, for a total transaction of $90,000.00. Following the purchase, the chief executive officer now owns 1,288,592 shares of the company's stock, valued at $773,155.20. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
PetVivo Trading Up 4.3 %
NASDAQ:PETV opened at $0.72 on Thursday. The company has a quick ratio of 0.62, a current ratio of 0.90 and a debt-to-equity ratio of 0.02. PetVivo Holdings, Inc. has a fifty-two week low of $0.33 and a fifty-two week high of $2.90. The firm's 50 day moving average is $1.04 and its two-hundred day moving average is $1.16.
PetVivo (NASDAQ:PETV - Get Free Report) last posted its quarterly earnings results on Monday, February 12th. The company reported ($0.12) earnings per share for the quarter. The company had revenue of $0.60 million for the quarter. PetVivo had a negative return on equity of 1,319.59% and a negative net margin of 1,016.64%.
Institutional Investors Weigh In On PetVivo
Have You Seen Elon’s New A.I. Device? (Picture Inside)
From InvestorPlace | Ad
A strange new era for mankind is upon us...
And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day.
Elon believes A.I. is advancing so fast...
This strange new device to protect us against that A.I. threat...
Large investors have recently made changes to their positions in the business. Warberg Asset Management LLC acquired a new stake in shares of PetVivo in the fourth quarter worth $29,000. HighTower Advisors LLC acquired a new stake in shares of PetVivo in the first quarter worth $40,000. Finally, Vanguard Group Inc. increased its position in shares of PetVivo by 5.2% in the first quarter. Vanguard Group Inc. now owns 226,137 shares of the company's stock worth $461,000 after acquiring an additional 11,251 shares in the last quarter. Institutional investors and hedge funds own 24.55% of the company's stock.
About PetVivo
(
Get Free Report)
PetVivo Holdings, Inc, a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
